Some of the first results from clinical trials with Remdesivir, the drug being promoted as the answer to SARS-CoV-2 treatment, have been released and, so far, it doesn’t look so good.
Four of the five trial participants had adverse side effects, including renal failure with two patients requiring transplants.
In related news, members of the COVID-19 Treatment Guidelines Panel, which makes recommendations on treatments for the virus, had to disclose any financial conflicts they may have.
Eight members are receiving financial support in the way of research funds or consulting fees from Gilead, Remdesivir’s maker.
Published: July 10, 2020